Contact
searchSearch
HMP Global

Pharmacy Learning Network

PharmLaw

PharmLaw
Oregon AG Files $900M Lawsuit Alleging Insulin Price-Fixing Scheme Involving PBMs and Manufacturers
01/14/2026
Juliet Gallagher
Oregon Attorney General Dan Rayfield has filed a sweeping lawsuit against 3 of the nation’s largest insulin manufacturers and 3 major pharmacy benefit managers (PBMs), alleging a coordinated scheme to artificially inflate insulin prices at...
Oregon Attorney General Dan Rayfield has filed a sweeping lawsuit against 3 of the nation’s largest insulin manufacturers and 3 major pharmacy benefit managers (PBMs), alleging a coordinated scheme to artificially inflate insulin prices at...
Oregon Attorney General Dan...
01/14/2026
Pharmacy Learning Network
PharmLaw
Jefferson Health Alleges Insulin Rebate Scheme Between PBMs and Drugmakers
01/09/2026
Juliet Gallagher
A major nonprofit health system has filed a federal lawsuit accusing leading insulin manufacturers and pharmacy benefit managers (PBMs) of conspiring to inflate insulin prices through rebate-driven pricing practices that allegedly harm...
A major nonprofit health system has filed a federal lawsuit accusing leading insulin manufacturers and pharmacy benefit managers (PBMs) of conspiring to inflate insulin prices through rebate-driven pricing practices that allegedly harm...
A major nonprofit health system...
01/09/2026
Pharmacy Learning Network
PharmLaw
West Virginia Files Lawsuit Alleging Optum’s PBM Practices Contributed to Opioid Crisis
12/10/2025
Danielle Sposato
West Virginia has sued Optum, alleging the PBM’s rebate-driven formulary practices, manufacturer collaborations, data sharing, mail-order dispensing, and discount card programs contributed to the state’s opioid crisis. The lawsuit seeks...
West Virginia has sued Optum, alleging the PBM’s rebate-driven formulary practices, manufacturer collaborations, data sharing, mail-order dispensing, and discount card programs contributed to the state’s opioid crisis. The lawsuit seeks...
West Virginia has sued Optum,...
12/10/2025
Pharmacy Learning Network
PharmLaw
CVS to Pay $37.76 Million to Resolve Federal Allegations of Over-Dispensing Insulin Pens
12/05/2025
Danielle Sposato
The US Attorney’s Office for the Southern District of New York has announced a $37.76 million settlement with CVS Pharmacy, Inc. to resolve allegations that the company violated the False Claims Act by over-dispensing insulin pens and...
The US Attorney’s Office for the Southern District of New York has announced a $37.76 million settlement with CVS Pharmacy, Inc. to resolve allegations that the company violated the False Claims Act by over-dispensing insulin pens and...
The US Attorney’s Office for the...
12/05/2025
Pharmacy Learning Network
PharmLaw
FTC Action Against Caremark & Zinc Health Services Sparks Proposed Regulatory Overhaul of Insulin Pricing Practices
11/26/2025
Danielle Sposato
The Federal Trade Commission’s enforcement action against Caremark Rx, LLC, Zinc Health Services, LLC, and related entities—which centers on how pharmacy benefit managers (PBMs) and their affiliated group purchasing organizations (GPOs)...
The Federal Trade Commission’s enforcement action against Caremark Rx, LLC, Zinc Health Services, LLC, and related entities—which centers on how pharmacy benefit managers (PBMs) and their affiliated group purchasing organizations (GPOs)...
The Federal Trade Commission’s...
11/26/2025
Pharmacy Learning Network

FDA Recalls

News
Imprimis NJOF Initiates Class II Recall of Tri-Moxi+ Intraocular Injection Due to Particulate Matter
01/15/2026
Juliet Gallagher
Imprimis NJOF, LLC is recalling Tri-Moxi+® (Triamcinolone 9 mg/0.6 mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, NDC 71384-746-06. The recall encompasses 314 boxes totaling 6280 pre-filled syringes. Affected product...
Imprimis NJOF, LLC is recalling Tri-Moxi+® (Triamcinolone 9 mg/0.6 mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, NDC 71384-746-06. The recall encompasses 314 boxes totaling 6280 pre-filled syringes. Affected product...
Imprimis NJOF, LLC is recalling...
01/15/2026
Pharmacy Learning Network
News
FDA Reports Class II Recall of Imprimis Intraocular Dexamethasone Injections Due to Glass Particulates
01/15/2026
Juliet Gallagher
Imprimis NJOF, LLC is recalling two compounded intraocular injectable drug products distributed nationwide in the US. The first product, Dexamethasone Moxifloxacin Intraocular Injection (1 mg/mL and 5 mg/mL, 1 mL, Rx only; NDC 71384-512-0.1),...
Imprimis NJOF, LLC is recalling two compounded intraocular injectable drug products distributed nationwide in the US. The first product, Dexamethasone Moxifloxacin Intraocular Injection (1 mg/mL and 5 mg/mL, 1 mL, Rx only; NDC 71384-512-0.1),...
Imprimis NJOF, LLC is recalling...
01/15/2026
Pharmacy Learning Network
News
SpecGx Initiates Class II Recall of Oxycodone/Acetaminophen Tablets Over Missing Imprint Risk
01/15/2026
Juliet Gallagher
SpecGx, LLC is recalling Oxycodone and Acetaminophen CII Tablets USP, 10 mg/325 mg, packaged in bottles of 100 tablets and labeled with NDC 0406-0523-01. The affected lots include 0523J23904 (expiration May 2027) and 0523J24426 and 0523J24427...
SpecGx, LLC is recalling Oxycodone and Acetaminophen CII Tablets USP, 10 mg/325 mg, packaged in bottles of 100 tablets and labeled with NDC 0406-0523-01. The affected lots include 0523J23904 (expiration May 2027) and 0523J24426 and 0523J24427...
SpecGx, LLC is recalling...
01/15/2026
Pharmacy Learning Network
News
BD ChloraPrep Triple Swabsticks Recalled Due to Sterility Concerns
01/07/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for BD ChloraPrep Triple Swabsticks due to a lack of sterility assurance, potentially compromising infection control in preoperative and clinical use.
The US Food and Drug Administration (FDA) has issued a Class II recall for BD ChloraPrep Triple Swabsticks due to a lack of sterility assurance, potentially compromising infection control in preoperative and clinical use.
The US Food and Drug...
01/07/2026
Pharmacy Learning Network
News
Class II Recall for Ondansetron Orally Disintegrating Tablets Due to Packaging Defect
01/07/2026
Hannah Musick
A Class II recall for Ondansetron Orally Disintegrating Tablets has been issued due to defective blister packaging that may allow tablets to fall out, potentially compromising product integrity and dosing accuracy.
A Class II recall for Ondansetron Orally Disintegrating Tablets has been issued due to defective blister packaging that may allow tablets to fall out, potentially compromising product integrity and dosing accuracy.
A Class II recall for...
01/07/2026
Pharmacy Learning Network

In the News

News
Imprimis NJOF Initiates Class II Recall of Tri-Moxi+ Intraocular Injection Due to Particulate Matter
01/15/2026
Juliet Gallagher
Imprimis NJOF, LLC is recalling Tri-Moxi+® (Triamcinolone 9 mg/0.6 mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, NDC 71384-746-06. The recall encompasses 314 boxes totaling 6280 pre-filled syringes. Affected product...
Imprimis NJOF, LLC is recalling Tri-Moxi+® (Triamcinolone 9 mg/0.6 mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, NDC 71384-746-06. The recall encompasses 314 boxes totaling 6280 pre-filled syringes. Affected product...
Imprimis NJOF, LLC is recalling...
01/15/2026
Pharmacy Learning Network
News
FDA Reports Class II Recall of Imprimis Intraocular Dexamethasone Injections Due to Glass Particulates
01/15/2026
Juliet Gallagher
Imprimis NJOF, LLC is recalling two compounded intraocular injectable drug products distributed nationwide in the US. The first product, Dexamethasone Moxifloxacin Intraocular Injection (1 mg/mL and 5 mg/mL, 1 mL, Rx only; NDC 71384-512-0.1),...
Imprimis NJOF, LLC is recalling two compounded intraocular injectable drug products distributed nationwide in the US. The first product, Dexamethasone Moxifloxacin Intraocular Injection (1 mg/mL and 5 mg/mL, 1 mL, Rx only; NDC 71384-512-0.1),...
Imprimis NJOF, LLC is recalling...
01/15/2026
Pharmacy Learning Network
News
SpecGx Initiates Class II Recall of Oxycodone/Acetaminophen Tablets Over Missing Imprint Risk
01/15/2026
Juliet Gallagher
SpecGx, LLC is recalling Oxycodone and Acetaminophen CII Tablets USP, 10 mg/325 mg, packaged in bottles of 100 tablets and labeled with NDC 0406-0523-01. The affected lots include 0523J23904 (expiration May 2027) and 0523J24426 and 0523J24427...
SpecGx, LLC is recalling Oxycodone and Acetaminophen CII Tablets USP, 10 mg/325 mg, packaged in bottles of 100 tablets and labeled with NDC 0406-0523-01. The affected lots include 0523J23904 (expiration May 2027) and 0523J24426 and 0523J24427...
SpecGx, LLC is recalling...
01/15/2026
Pharmacy Learning Network
PharmLaw
Oregon AG Files $900M Lawsuit Alleging Insulin Price-Fixing Scheme Involving PBMs and Manufacturers
01/14/2026
Juliet Gallagher
Oregon Attorney General Dan Rayfield has filed a sweeping lawsuit against 3 of the nation’s largest insulin manufacturers and 3 major pharmacy benefit managers (PBMs), alleging a coordinated scheme to artificially inflate insulin prices at...
Oregon Attorney General Dan Rayfield has filed a sweeping lawsuit against 3 of the nation’s largest insulin manufacturers and 3 major pharmacy benefit managers (PBMs), alleging a coordinated scheme to artificially inflate insulin prices at...
Oregon Attorney General Dan...
01/14/2026
Pharmacy Learning Network
PharmLaw
Jefferson Health Alleges Insulin Rebate Scheme Between PBMs and Drugmakers
01/09/2026
Juliet Gallagher
A major nonprofit health system has filed a federal lawsuit accusing leading insulin manufacturers and pharmacy benefit managers (PBMs) of conspiring to inflate insulin prices through rebate-driven pricing practices that allegedly harm...
A major nonprofit health system has filed a federal lawsuit accusing leading insulin manufacturers and pharmacy benefit managers (PBMs) of conspiring to inflate insulin prices through rebate-driven pricing practices that allegedly harm...
A major nonprofit health system...
01/09/2026
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use